Abstracts Archive - Page 593 of 2607 - ACR Meeting Abstracts

Abstract Number: 1656 • ACR Convergence 2022
Efficacy and Safety of Cenerimod in Patients with Moderate to Severe Systemic Lupus Erythematosus (SLE): A Multicenter, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled, Dose-Finding Phase 2b Trial
Anca Askanase¹, Ouali Berkani², clélia Cahuzac³, peter Cornelisse³, David D'Cruz⁴, Kenneth Kalunian⁵, Joan Merrill⁶, Marilia Pozzobon³ and Sandra Navarra⁷, ¹Columbia University Medical Center, New York, NY, ²IDORSIA, Allschwil, Switzerland, ³Idorsia Pharmaceuticals Ltd, Allschwil, Switzerland, ⁴Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom, ⁵University of California San Diego, La Jolla, CA, ⁶Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁷University of Santo Tomas, Manila, Philippines
Background/Purpose: Sphingosine-1-phosphate (S1P) regulates lymphocyte egress from lymphoid organs. In an SLE proof-of-concept study, cenerimod—a potent, selective S1P receptor modulator—reduced lymphocyte count and disease activity…
Abstract Number: 1657 • ACR Convergence 2022
Extreme Phenotype Approach Identifies Rare Variants in Systemic Sclerosis and Dermatomyositis Patients with Severe Calcinosis
Srijana Davuluri¹, Urvashi Kaundal², Christian Lood³, Puneet Kapoor¹, Yumeko Kawano⁴, Stefania Dell'Orso⁵, Zuoming Deng⁶, Zsuzsanna McMahan⁷, Ami Shah⁷, Laura Hummers⁸, Daniel Kastner⁹, Fredrick Wigley¹⁰, David Fiorentino¹¹, Pravitt Gourh¹² and Lorinda Chung¹¹, ¹Stanford University School of Medicine, Palo Alto, CA, ²National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, ³Division of Rheumatology, University of Washington, Seattle, WA, ⁴Brigham and Women's Hospital, Boston, MA, ⁵NIH, Bethesda, MD, ⁶National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ⁷Johns Hopkins Rheumatology, Baltimore, MD, ⁸Johns Hopkins Univerisity, Baltimore, MD, ⁹National Human Genome Research Institute, Bethesda, MD, ¹⁰Johns Hopkins University, Baltimore, MD, ¹¹Stanford University, Stanford, CA, ¹²National Institutes of Health, Bethesda, MD
Background/Purpose: Calcinosis, deposition of insoluble calcium salts in skin and subcutaneous tissues, affects up to 40% of systemic sclerosis (SSc) patients, and up to 20%…
Abstract Number: 1647 • ACR Convergence 2022
Increased Risk of Lung Cancer in Rheumatoid Arthritis and Rheumatoid Arthritis-Associated Interstitial Lung Disease: A Matched Cohort Study with Cancer Registry Linkage
Rebecca Brooks¹, Yangyuna Yang¹, Punyasha Roul², Brent Luedders¹, Namrata Singh³, Brian Sauer⁴, Grant Cannon⁵, Joshua Baker⁶, Ted Mikuls⁷ and Bryant England¹, ¹University of Nebraska Medical Center, Omaha, NE, ²UNMC, Omaha, NE, ³University of Washington, Bellevue, WA, ⁴Salt Lake City VA/University of Utah, Salt Lake City, UT, ⁵Retired, Salt Lake City, UT, ⁶University of Pennsylvania, Philadelphia, PA, ⁷Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: While patients with RA are predisposed to developing lung cancer, prior epidemiologic studies have been limited in their ability to account for potential confounders…
Abstract Number: 1655 • ACR Convergence 2022
Belimumab Disrupts Memory B-Cell Trafficking in Patients with Systemic Lupus Erythematosus
Eline J. Arends¹, Mihaela Zlei², Christopher M. Tipton³, Jasna Cotic⁴, Zgjim Osmani¹, Fenna J. De Bie², Sylvia W.A. Kamerling¹, Andre Van Maurik⁵, Richard Dimelow⁶, Yun Irene Gregan⁷, Norma Lynn Fox⁸, Ton J. Rabelink¹, David A. Roth⁹, Iñaki Sanz¹⁰, Jacques J.M. Van Dongen², Cees Van Kooten¹ and Onno Teng¹¹, ¹Department of Nephrology, Leiden University Medical Center, Leiden, Netherlands, ²Department of Immunology, Leiden University Medical Center, Leiden, Netherlands, ³Lowance Center for Human Immunology, Emory University School of Medicine, Atlanta, GA, ⁴Clinical Statistics, GlaxoSmithKline, Brentford, United Kingdom, ⁵GlaxoSmithKline, Clinical Pharmacology and Experimental Medicine, Stevenage, United Kingdom, ⁶GlaxoSmithKline, Clinical Biomarker Group, Stevenage, United Kingdom, ⁷GlaxoSmithKline, Clinical Science Immunology, Collegeville, PA, ⁸GlaxoSmithKline, Clinical Development *At time of study, Collegeville, PA, ⁹GlaxoSmithKline, Research and Development, Collegeville, PA, ¹⁰Emory University, Atlanta, GA, ¹¹Leiden University Medical Center, Leiderdorp, Netherlands
Background/Purpose: Belimumab (BEL), a recombinant human monoclonal antibody directed against B-cell activating factor (BAFF), is the first approved biological agent for patients (pts) with active…
Abstract Number: 1668 • ACR Convergence 2022
Rheumatic Toxicities of Immune Checkpoint Inhibitors Predict Favourable Tumour Responses in Patients with Advanced Melanoma
Alana Bruce¹, Alexander M Menzies², Georgina V Long², Brian Fernandes³ and Fredrick Joshua⁴, ¹Macquarie University, Balaclava, Victoria, Australia, ²Melanoma Institute Australia, The University of Sydney, Royal North Shore and Mater Hospitals, Sydney, Australia, ³Royal Prince Alfred Hospital, Sydney, Australia, ⁴Macquarie University, Integrated Specialist Medical Care, Sydney, Australia
Background/Purpose: To estimate the frequency of rheumatic toxicities of immune checkpoint inhibitors (ICI) presenting as de novo or exacerbations of pre-existing rheumatic disease in patients…
Abstract Number: 1662 • ACR Convergence 2022
Nationwide Distribution of Other Connective Tissue Disease (OCTD) and Systemic Sclerosis (SSc) in Areas of Environmental Concern
Noelle Kosarek¹, Megan Romano², Robert Simms³, Angeline Andrew⁴, Erika Moen⁴, Patricia pioli⁴ and Michael Whitfield⁵, ¹Dartmouth Geisel School of Medicine, Lebanon, NH, ²Dartmouth College, Lebanon, NH, ³Dartmouth Hitchcock Medical Center, Lebanon, NH, ⁴Geisel School of Medicine at Dartmouth, Lebanon, NH, ⁵Dartmouth Geisel School of Medicine, Department of Biomedical Data Science, Lebanon, NH
Background/Purpose: Systemic sclerosis (SSc) is a rare autoimmune disease characterized by fibrosis of the skin and internal organs, vascular abnormalities, and autoantibody formation. The etiology…
Abstract Number: 1664 • ACR Convergence 2022
TRIM21 as a Regulator of UVB-Driven IFN Responses in Lupus
Richard Moore, Gantsetseg Tumurkhuu, Daniel Wallace and Caroline Jefferies, Cedars-Sinai Medical Center, Los Angeles, CA
Background/Purpose: Patients with systemic lupus erythematosus (SLE) experience photosensitivity where exposure to ultraviolet light B (UVB) drives lupus flares and systemic symptoms. Although the mechanisms…
Abstract Number: 1660 • ACR Convergence 2022
Skeletal Myopathy in Systemic Sclerosis Associates with Higher Disease Burden and Mortality
Julie Paik¹, Caoilfhionn Connolly¹, Fredrick Wigley¹ and Laura Hummers², ¹Johns Hopkins University, Baltimore, MD, ²Johns Hopkins Univerisity, Baltimore, MD
Background/Purpose: Skeletal myopathy in systemic sclerosis (SSc) is poorly understood. The etiology of myopathy in SSc is heterogeneous and can result from an inflammation, disuse,…
Abstract Number: 1671 • ACR Convergence 2022
Current Cervical Cancer Screening Guidelines Are Unsatisfactory for the Needs of Systemic Lupus Erythematosus Patients
Zehra Kazmi¹, Carlos Lorenzo¹, Farwa Kazmi² and Agustin Escalante³, ¹University of Texas Health Sciences Center San Antonio, San antonio, TX, ²Gulf Medical University, Ajman, United Arab Emirates, ³University of Texas Health Science Center at San Antonio, San Antonio, TX
Background/Purpose: HPV infection is a risk factor for cervical cancer. SLE patients have increased rates of HPV infection, cervical dysplasia and cancer. Present guidelines for…
Abstract Number: 1673 • ACR Convergence 2022
Preconceptional NSAID Treatment Exposure Is Associated with a Significantly Longer Time-to-conception in Women with Spondyloarthritis: Analysis of the Prospective GR2 Cohort
SABRINA HAMROUN¹, Marion Couderc², Rene-Marc Flipo³, Jérémie SELLAM⁴, Christophe Richez⁵, Emmanuelle Dernis⁶, Aline Frazier-Mironer⁷, Laure Gossec⁸, elisabeth gervais⁹, Hubert Marotte¹⁰, Laetitia Dunogeant¹¹, Cédric Lukas¹², Alban DEROUX¹³, Nathalie Costedoat-Chalumeau¹⁴ and Anna Molto¹⁵, ¹Rheumatology Department, University Hospital of Cochin, Paris, Paris, France, ²University Hospital, Clermont-Ferrand, France, ³CHU Lille, Boulogne-Billancourt, France, ⁴Sorbonne Universite, AP-HP, Saint-Antoine hospital, Paris, France, ⁵Université de Bordeaux, Bordeaux, France, ⁶LE MANS general hospital, LE MANS, France, ⁷APHP Hôpital Lariboisire, Paris, France, ⁸Sorbonne Université, Paris, France, ⁹chu poitiers, Poitiers, France, ¹⁰INSERM 1059, Saint-Etienne, France, ¹¹Hospital of Aix en Provence, Marseille, France, ¹²University Hospital Centre Montpellier, University of Montpellier, Montpellier, France, ¹³CHU Grenoble, Grenoble, France, ¹⁴Inserm DR Paris 5, Paris, France, ¹⁵Rheumatology Department, Cochin Hospital, APHP, Paris, France
Background/Purpose: Spondyloarthritis (SpA) is one of the most common chronic inflammatory diseases and regularly affects women of childbearing age. However, there is limited knowledge about…
Abstract Number: 1670 • ACR Convergence 2022
Phase II Clinical Trial to Assess the Safety and Efficacy of Tocilizumab in Combination with Ipilimumab and Nivolumab for Treatment-naïve Metastatic Melanoma
Noha Abdel-Wahab¹, Emma J. Montazari¹, Christine A. Spillson¹, Salah-Eddine Bentebibel¹, Jean H. Tayar¹, Maria Suarez-Almazor², Suhendan Ekmekcioglu¹, Daniel H. Johnson³ and Adi Diab¹, ¹UT MD Anderson Cancer Center, Houston, TX, ²MD Anderson Cancer Center, Houston, TX, ³Ochsner Health, New Orleans, LA
Background/Purpose: Immune checkpoint inhibitors (ICIs) led to impressive survival benefits in treatment of cancers. However, immune-related adverse events (irAEs) can cause treatment discontinuation and sometimes…
Abstract Number: 1672 • ACR Convergence 2022
The Impact of Systemic Sclerosis (SSc) on Women’s Health Evaluated with a New SSc-specific Patient-reported Questionnaire
Maria Grazia Lazzaroni¹, Liala Moschetti¹, Eleonora Pedretti¹, Andrea Lojacono², Francesca Ramazzotto³, Cristina Zanardini³, Zatti Sonia³, Angela Tincani⁴, Franco Franceschini¹, Paolo Airò⁵ and Laura Andreoli¹, ¹Rheumatology and Clinical Immunology Unit, ASST Spedali Civili and University of Brescia, Brescia, Italy, ²Obstetrics and Gynecology, ASST Garda, Desenzano del Garda, Brescia, Brescia, Italy, ³Obstetrics and Gynecology, ASST Spedali Civili and University of Brescia, Brescia, Italy, ⁴Rheumatology and Clinical Immunology Unit, ASST Spedali Civili and University of Brescia, Gussago, Italy, ⁵Rheumatology and Clinical Immunology Unit, ASST Spedali Civili, Brescia, Italy
Background/Purpose: Systemic Sclerosis (SSc) has a strong female predominance and can significantly impair the everyday quality of life of patients. We aimed at designing a…
Abstract Number: 1163 • ACR Convergence 2022
Proteomic Investigation to Identify Urinary Biomarker for Ankylosing Spondylitis
Ji-Hyun Lee¹, Jeesoo Kim², Sang-Hyon kim¹, Jong‑Seo kim² and Chang-Nam son¹, ¹Keimyung University, Dalseo-gu, Daegu, Republic of Korea, ²seoul national university, Seoul, Republic of Korea
Background/Purpose: Ankylosing spondylitis (AS) is a chronic inflammatory rheumatic disease that affects the spine and peripheral joints, and the exact etiology is still unknown. Diagnosis…
Abstract Number: 1614 • ACR Convergence 2022
Females with Non-Radiographic but Not with Radiographic Axial Spondyloarthritis Are Less Likely to Achieve Inactive Disease State Than Males: Results from a Multicountry Prospective Observational Study
Denis Poddubnyy¹, Joachim Sieper², Servet Akar³, Santiago Muñoz-Fernández⁴, Hildrun Haibel², Torsten Diekhoff⁵, Mikhail Protopopov⁶, Elisabeth Altmaier⁷, Fabiana Ganz⁸ and Robert Inman⁹, ¹Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité – Universitätsmedizin Berlin, Berlin, Germany, ²Charité - Universitätsmedizin, Berlin, Berlin, Germany, ³Izmir Katip Celebi University School of Medicine, Izmir, Turkey, ⁴Servicio de Reumatología, Hospital Universitario Infanta Sofía, Universidad Europea, Madrid, Spain, ⁵Department of Radiology, Charité-Universitätsmedizin Berlin, Berlin, Germany, ⁶Charité Universitätsmedizin Berlin, Berlin, Germany, ⁷GKM Gesellschaft für Therapieforschung mbH, Munich, Germany, ⁸AbbVie, Inc., Luzern, Switzerland, ⁹University Health Network, Toronto, ON, Canada
Background/Purpose: Emerging evidence suggests that men and women experience axial spondyloarthritis (axSpA) differently. Some studies suggested that the probability of treatment response was lower in…
Abstract Number: 1564 • ACR Convergence 2022
Anti-TNF versus Anti-IL6 Receptor Antagonist Therapy in Severe Ocular Involvement in Behçet’s Disease
Nuria Barroso-García¹, Belén Atienza-Mateo², Ivan Ferraz Amaro³, Diana Prieto-Peña², Ana De Vicente-Delmás⁴, Ricardo Blanco⁵ and Miguel Ángel González-Gay⁶, ¹Hospital Universitario Puerta del Mar, Cádiz, Spain, Cádiz, Spain, ²Research Group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL; and Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ³Division of Rheumatology. Hospital Universitario de Canarias. Spain., Santa Cruz de Tenerife, Spain, ⁴Hospital General Santa María del Puerto, Cádiz, Spain, ⁵Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ⁶Department of Medicine and Psychiatry, Universidad de Cantabria; Rheumatology Division, Hospital Universitario Marqués de Valdecilla; Research group on genetic epidemiology and atherosclerosis in systemic diseases and in metabolic diseases of the musculoskeletal system, IDIVAL, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
Background/Purpose: To evaluate the efficacy of anti-TNF or anti-IL6 treatment in severe and refractory ocular involvement in patients with refractory cystoid macular edema (CME) due…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].